News

hMPV is likely one of the viruses making us sick this season. Here's what to know about human metapneumovirus
As winter settles over Australia, it's not just the drop in temperature we notice—there's also a sharp rise in respiratory ...
Newly approved antibody could offer another option for protecting infants from RSV, a common infection that can be deadly
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...
FDA expands approval of Moderna's RSV vaccine to some adults under age 60
The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...
FDA clears Moderna’s RSV vaccine for use in people ages 18 to 59
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...
The Manhattan Mercury2d
New Antibody Shot Could Help Protect Babies From RSV
THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial ...
BioSpace2d
As New CDC Vaccine Advisors Gear Up for First Meeting, Experts Ask, ‘Where’s Cassidy?’
Scientists and analysts express concern that the newly appointed members—which include known anti-vaxxers—could relitigate ...
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...
BioPharma Dive1d
Moderna wins FDA OK to widen use of RSV vaccine
The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...
Global Respiratory Syncytial Virus Treatment Market Size To Reach USD 8,332.5 Million By 2033 Astute Analytica
The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by rising vaccine uptake, impr ...
STAT1d
FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.